Gastrointestinal Stromal Tumor (GIST) is an indication for drug development with over 70 pipeline drugs currently active. According to GlobalData, preregistered drugs for Gastrointestinal Stromal Tumor (GIST) have a 80% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Gastrointestinal Stromal Tumor (GIST) compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gastrointestinal Stromal Tumor (GIST) overview
Gastrointestinal stromal tumors (GISTs) are tumors that occur in the gastrointestinal tract. GISTs belong to a group of cancers called soft tissue sarcomas. GISTs can be benign or malignant. The symptoms of GIST include pain or discomfort in the abdomen, a mass in the abdomen that can be felt with the hand, nausea and vomiting, vomiting blood or having blood in the stool, and fatigue due to anemia (low red blood cell counts). GIST treatment involves surgery, radiation therapy, targeted therapy, and chemotherapy.
For a complete picture of PTSR and LoA scores for drugs in Gastrointestinal Stromal Tumor (GIST), buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
